SenesTech Inc (SNES)

SenesTech Appoints Jack Karabees as Executive Vice President of SalesJune 29, 2026 8:30 AM
PR Newswire (US) Veteran enterprise sales executive brings decades of experience scaling companies and leading successful commercial organizationsSURPRISE, Ariz., June 29, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a leader in fertility control solutions for managing rodent populations, today announced the appointment of Jack Karabees as Executive Vice President of Sales. Mr. Karabees brings more than three decades of experience building and leading professional B2B sales organizations and helping companies define the processes and systems necessary to achieve significant scale. In his new role, he will lead SenesTech's sales organization and be responsible for driving revenue growth, expanding market penetration and strengthening customer relationships across key channels.Most recently, Mr. Karabees served as Chief Revenue Officer of Intercept Telehealth, a provider of virtual critical care and telehealth services to health systems and hospitals. Prior to Intercept, he served as President and Executive Vice President of Sales at Consult A Doctor, helping guide the company from startup through its successful acquisition by Teladoc Health (NYSE: TDOC).Earlier in his career, Mr. Karabees served as Executive Vice President of Corporate Finance, Sales and Marketing for Entic, a cloud-based predictive analytics and optimization platform serving hospitals and large healthcare facilities. During his tenure, the company was acquired by Blackstone Group and subsequently sold to Aquicore. He also served as Senior Vice President of Sales at eLabor, a cloud-based workforce management and human resources software provider, helping lead the company through growth that resulted in separate divisional acquisitions by Microsoft Corporation and ADP.Mr. Karabees served as Executive Vice President of Investment Banking with Katalyst Securities and has been active in the entrepreneurial and investment community, serving as both a member and board member of New World Angels and Miami Innovation Fund. Throughout his career, companies and entrepreneurs have benefited from Mr. Karabees' operational expertise and his ability to build and scale professional B2B sales organizations. Mr. Karabees is a veteran of the United States Air Force and resides in Coral Gables, Florida, with his wife and two daughters.In addition, Mr. Karabees has been working closely with SenesTech in a consulting capacity, providing strategic guidance and supporting the Company's commercial initiatives. His appointment represents the next step in his involvement with the Company as SenesTech continues to build a professional sales organization and pursue its growth opportunities."Jack has built and led successful professional B2B sales organizations throughout his career and has extensive experience helping companies define the processes and systems necessary to achieve significant scale," said Michael Edell, President and Chief Executive Officer of SenesTech. "Having worked with Jack for years at other companies and alongside him at SenesTech, I have seen firsthand what he is capable of building. We know there is a significant opportunity for our rodent birth control products not only in the direct-to-consumer market, but also across a number of B2B verticals, and we believe Jack's experience and leadership will help us capitalize on those opportunities and accelerate the Company's growth."Mr. Karabees added, "SenesTech has developed patented products, marketed under its Evolve and ContraPest brands, to address an immense problem in rodent population management, and I believe there is a tremendous opportunity for the Company across multiple markets. I am excited to join the team and look forward to building on the strong foundation already in place and helping the Company capitalize on the opportunities ahead."About SenesTech, Inc. SenesTech is the leader in rodent birth control solutions. The Company's patented products, marketed under its Evolve™ and ContraPest® brands, provide effective, sustainable approaches to long-term rodent population management that can be integrated into existing pest management programs or used independently. SenesTech serves both consumer and professional markets with science-based solutions aimed at addressing one of the world's most persistent pest challenges.For more information, visit https://senestech.com.  Safe Harbor StatementThis press release contains forward-looking statements within the meaning of federal securities laws.  Such forward-looking statements include, among others, statements regarding the development of the Company's sales organization and growth opportunities, the potential opportunity for the Company's rodent birth control products in the direct-to-consumer market and across B2B verticals, and the new Executive Vice President of Sales' ability to help the Company capitalize on those opportunities and accelerate growth.You are cautioned that such statements are based on current expectations and assumptions and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the risk that the Company may not be successful in the commercialization of its products, or realize sufficient market acceptance of its products, or capitalize on market opportunities and accelerate growth; risks related to the Company's financial performance, including the ability to fund its ongoing operations; risks related to required regulatory approvals for and regulation of the Company's products; and other factors and risks identified from time to time in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, the Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.Investor Contact:
Robert Blum, Lytham Partners, LLC
(602) 889-9700, senestech@lythampartners.comCompany Contact:
Tom Chesterman, SenesTech, Inc.
(928) 233-7533, investors@senestech.com View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-appoints-jack-karabees-as-executive-vice-president-of-sales-302812733.htmlSOURCE SenesTech, Inc. Original: SenesTech Appoints Jack Karabees as Executive Vice President of Sales

SenesTech Expands Distribution of Evolve® Rodent Birth Control™ into BermudaJune 4, 2026 8:00 AM
PR Newswire (US) SURPRISE, Ariz., June 4, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a leader in birth control solutions for managing rodent populations, today announced the expansion of its Evolve® Rodent Birth Control™ products into Bermuda through a distribution agreement with Animal and Garden House, marking another step in the Company's growing presence in environmentally sensitive island markets. "Bermuda presents a unique environment for pest management solutions. As a small island with a dense population and close proximity between urban areas and surrounding marine ecosystems, the use of traditional rodenticides has long required careful consideration. Concerns regarding runoff, non-target exposure, and impacts on wildlife have contributed to a highly controlled regulatory environment governing pesticide importation and use," said Jennifer McCarron of Animal and Garden House. "Evolve Rodent Birth Control offers a novel approach to managing rodent populations by reducing fertility rather than relying solely on lethal methods. Designed to integrate into existing pest management programs, we believe Evolve provides an effective and sustainable solution that can be used alongside or in place of traditional rodenticides.""Bermuda represents an ideal market for Evolve," said Michael Edell, President and CEO of SenesTech. "The island's focus on environmental stewardship, together with the realities of rodent control in a compact and interconnected ecosystem, underscores the importance of solutions that go beyond conventional methods. Bermuda is part of a broader network of environmental leaders and organizations across the Caribbean and other sensitive ecosystems that understand how quickly ecological impacts can extend beyond local boundaries. We feel Evolve is well positioned to support those long-term sustainability objectives."Other existing and expanding deployments of Evolve in the area include the U.S. Virgin Islands and Belize.About SenesTech, Inc. SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.For more information, visit https://senestech.com.Safe Harbor StatementThis press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements include, among others, statements regarding anticipated benefits from the distribution agreement with Animal and Garden House, and Evolve's ability to provide an effective and sustainable solution to support long-term sustainability objectives and be used alongside or in place of traditional rodenticides. You are cautioned that such statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, among others, the risk that the distribution agreement with Animal and Garden House may not provide the benefits expected, variability in field conditions, implementation practices, market acceptance of our products, regulatory considerations, and other risks described in SenesTech's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them except as required by law.Investor Contact:
Robert Blum, Lytham Partners, LLC
(602) 889-9700, senestech@lythampartners.comCompany Contact:
Tom Chesterman, SenesTech, Inc.
(928) 233-7533, investors@senestech.com View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-expands-distribution-of-evolve-rodent-birth-control-into-bermuda-302790847.htmlSOURCE SenesTech, Inc. Original: SenesTech Expands Distribution of Evolve® Rodent Birth Control™ into Bermuda

SenesTech Announces Amendment to Equity Incentive Plan ProposalJune 3, 2026 4:05 PM
PR Newswire (US) PHOENIX, June 3, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) ("SenesTech" or the "Company"), today announced that its Board of Directors has approved an amendment to the proposed changes to the Company's 2018 Equity Incentive Plan (the "2018 Plan"), which is being presented for stockholder approval at the Company's 2026 Annual Meeting of Stockholders scheduled for June 9, 2026. As previously disclosed in the Company's definitive Proxy Statement filed on April 29, 2026, stockholders are being asked to approve an amendment to the 2018 Plan to increase the number of shares available for future equity awards. Following further review of the Company's anticipated equity compensation needs, current market conditions and stockholder considerations, the Board approved a revised amendment that reduces the number of new shares proposed to be added to the 2018 Plan from 1.7 million shares to 1.2 million shares. The Board believes these actions reflect a balanced approach to equity compensation and capital management.Stockholders who have already submitted, or subsequently submit, a proxy card or vote via the Internet or by telephone in favor of Proposal No. 3 will be deemed to have voted in favor of Proposal No. 3 as revised by the supplemental proxy materials. Accordingly, no additional action is required from stockholders who have previously voted in favor of Proposal No. 3 and do not wish to change their vote.Additional information regarding the revised proposal is contained in the Company's definitive additional proxy materials filed with the Securities and Exchange Commission on May 27, 2026.About SenesTech, Inc. SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.
For more information, visit https://senestech.com. Safe Harbor StatementThis press release contains forward-looking statements within the meaning of federal securities laws. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, among others, variability in field conditions, implementation practices, market acceptance of our products, regulatory considerations, and other risks described in SenesTech's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them except as required by law.Investor Contact:
Robert Blum, Lytham Partners, LLC
(602) 889-9700, senestech@lythampartners.com Company Contact:
Tom Chesterman, SenesTech, Inc.
(928) 233-7533, investors@senestech.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-amendment-to-equity-incentive-plan-proposal-302790611.htmlSOURCE SenesTech, Inc. Original: SenesTech Announces Amendment to Equity Incentive Plan Proposal

SenesTech to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026May 19, 2026 4:30 PM
PR Newswire (US) SURPRISE, Ariz., May 19, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast
The webcast presentation will take place at 2:30 p.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.webinar.net/yq6rxLqNPWj. The webcast will also be available for replay following the event.1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/spring2026invreg/.    About SenesTech
SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The Company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.For more information visit https://senestech.com/.Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, statements regarding the acceleration of the Company's direct-to-consumer and e-commerce initiatives, the recurring nature of the Company's growing director-to-consumer business model, any growth attributable to the appointment of the Company's new CEO, the Company's efforts in driving B2B revenues, any increases in conversion rates and subscription growth, and any international expansion opportunities for the Company.Forward-looking statements may describe future expectations, plans, results, or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; regulatory approval and regulation of our products; challenges transitioning to direct management of Amazon sales of Evolve products or the results of such direct management not being as expected; having to use cash at times and in ways other than as planned; and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACT:Investors: Robert Blum, Lytham Partners, LLC, (602) 889-9700, senestech@lythampartners.comCompany: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., (928) 779-4143 View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-to-participate-in-the-lytham-partners-spring-2026-investor-conference-on-may-28-2026-302776442.htmlSOURCE SenesTech, Inc. Original: SenesTech to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

SenesTech Reports Record Direct-to-Consumer and Subscription Growth Following Strategic E-Commerce TransitionMay 12, 2026 4:05 PM
PR Newswire (US) In-house e-commerce transition and new CEO expected to support scalable recurring revenue growth strategySURPRISE, Ariz., May 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced financial results for the first quarter ended March 31, 2026 and provided an update on the Company's acceleration of revenue under newly appointed Chief Executive Officer, Michael Edell. Q1 2026 Financial HighlightsRevenue increased 2% to $493,000 in Q1 2026 compared to $485,000 in Q1 2025, despite approximately $157,000 of reduced third-party e-commerce revenue associated with the Company's transition from third-party e-commerce management to in-house management of Amazon sales. Gross profit increased 8% to $338,000 in Q1 2026 compared to $313,000 in Q1 2025.Direct-to-consumer revenue increased 42% to $194,000 in Q1 2026, compared to $137,000 in Q1 2025, driven by strong Amazon execution and continued subscription growth.Subscription revenue increased 44% to $56,000 in Q1 2026, compared to $39,000 in Q1 2025, reinforcing the recurring nature of the Company's growing direct-to-consumer business model.Third party e-commerce revenues declined to $17,000 in Q1 2026 compared to $157,000 in Q1 2025 due to the transition to managing Amazon efforts internally.B2B revenue increased 57% to $298,000 in Q1 2026 compared to $190,000 in Q1 2025, reflecting continued traction across distributor, municipal, and professional channels.Gross margin expanded to a company record 68.6% in Q1 2026 as direct channel economics improved and pricing discipline strengthened.Net loss for Q1 2026 was $2.1 million, compared to $1.7 million in Q1 2025. Q1 2026 included $443,000 in severance costs and one-time legal expenses.Adjusted EBITDA loss was $1.6 million in Q1 2026, compared to $1.5 million in Q1 2025.Cash and equivalents totaled $6.8 million at quarter end, supporting ongoing operational execution and strategic initiatives.April 2026 E-Commerce MomentumApril 2026 represented the first full month following completion of the Company's Amazon transition from third-party e-commerce management to direct in-house management.E-commerce sales for April 2026 increased 163% to a record $146,000 compared to $56,000 during April 2025 and increased 47% compared to $99,000 during March 2026, providing early positive evidence for the Company's evolving e-commerce strategy.Subscription-based revenue increased 198% to a record $36,000 during April 2026 compared to $12,000 during April 2025, while subscription-based customers increased 109%, reinforcing the recurring nature of the Company's growing direct-to-consumer business model.Recent Operational and Strategic HighlightsAppointment of New CEO: Michael Edell's appointment as President and Chief Executive Officer in May 2026 reinforces SenesTech's focus on operational accountability, scalable growth, and disciplined execution. During his tenure as Interim Chief Operating Officer, Mr. Edell helped accelerate the Company's direct-to-consumer strategy, including the transition to direct Amazon management, subscription growth initiatives, packaging redesign efforts, and broader go-to-market execution across e-commerce, distributor, municipal, and other B2B channels.Amazon Direct Management Transition Completed: SenesTech substantially completed its transition from third party e-commerce management of Amazon sales of Evolve products during March 2026. The transition provides the Company with greater visibility into customer behavior, enhanced control over advertising and media buying, improved pricing visibility, stronger customer engagement opportunities, and greater control over overall channel economics.E-Commerce Website Redesign Underway: SenesTech continues to redesign the e-commerce section of SenesTech.com to improve customer experience, simplify navigation, increase conversion rates, and support subscription growth. The redesign is expected to align closely with updated packaging, digital advertising initiatives, and broader consumer marketing efforts, with launch currently targeted for Q3 2026.B2B Vertical Expansion Strategy: SenesTech continues to refine its B2B strategy with increased focus on large-scale opportunities across targeted verticals including pest management, agriculture, municipalities, distributors, and other commercial markets capable of generating larger dollar opportunities. The emphasis on direct-to-consumer growth is also expected to support B2B revenues through increased brand awareness and inbound lead generation.Packaging Refresh Initiative: SenesTech is implementing updated packaging designed to improve online and shelf visibility and strengthen differentiation.Municipal Deployment Growth: SenesTech continues to see increased municipal deployment activity across major urban markets, including Chicago, Boston, Washington, D.C., and New York City. The previously announced 12-month New York City rat contraception pilot program is expected to conclude this month.International Activity: SenesTech continues to pursue international expansion opportunities on an opportunistic basis, with a focus on countries that can move efficiently through the regulatory process with minimal incremental cost to the Company.Management Commentary"SenesTech is entering a new phase where we are building a more scalable, data-driven and recurring revenue business model around the growing demand for non-poison rodent management solutions," said Michael Edell, Chief Executive Officer of SenesTech. "The strategic transition to directly managing our Amazon business and revamping our online e-commerce store has significantly improved our visibility into customer behavior, advertising performance, subscriptions, and overall channel economics. We are already seeing strong momentum in our direct-to-consumer business, particularly through accelerating subscription adoption and improved Amazon execution."Mr. Edell continued, "Our efforts across Amazon, Shopify, packaging redesign, digital media buying, subscriptions, and customer engagement are all connected initiatives intended to reduce friction, improve conversion, increase customer retention, and create a stronger recurring revenue foundation. At the same time, we remain focused on improving operational discipline, maintaining strong gross margins and positioning the Company for scalable long-term growth.""Our first quarter results reflected the expected temporary disruption associated with transitioning Amazon operations in-house, however the underlying consumer demand trends and April proof points were highly encouraging," said Tom Chesterman, Chief Financial Officer of SenesTech. "Direct-to-consumer revenue increased 42% to a record $194,000 during Q1, gross margin expanded to a Company record 68.6%, and subscription-based sales continued to accelerate breaking past revenue numbers. We believe these trends support the long-term strategic value of directly controlling our e-commerce channels and building a more predictable recurring revenue mix."Use of Non-GAAP MeasureAdjusted EBITDA and Adjusted Net Loss are non-GAAP measures. However, these measures are not intended to be a substitute for those financial measures reported in accordance with GAAP. These measures have been included because management believes that, when considered together with the GAAP figures, they provide meaningful information related to operating performance and liquidity trends. We use these non-GAAP financial measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. These adjustments may be calculated by us differently than other companies that disclose measures with the same or similar term. See our attached financials for a reconciliation of the non-GAAP measures to the nearest GAAP measure.Conference Call DetailsDate: Tuesday, May 12, 2026.Time: 5:00 p.m. ET.Webcast: https://app.webinar.net/m976bqQblKE. Webcast Replay: Available for 90 days on the Company's website.About SenesTechSenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The Company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.For more information visit https://senestech.com/. Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, statements regarding the acceleration of the Company's direct-to-consumer and e-commerce initiatives, the recurring nature of the Company's growing director-to-consumer business model, any growth attributable to the appointment of the Company's new CEO, the Company's efforts in driving B2B revenues, any increases in conversion rates and subscription growth, and any international expansion opportunities for the Company.Forward-looking statements may describe future expectations, plans, results, or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; regulatory approval and regulation of our products; challenges transitioning to direct management of Amazon sales of Evolve products or the results of such direct management not being as expected; having to use cash at times and in ways other than as planned; and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACT:Investors: Robert Blum, Lytham Partners, LLC, (602) 889-9700, senestech@lythampartners.com Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., (928) 779-4143 SENESTECH, INC.BALANCE SHEETS(In thousands, except share and per share data)(Unaudited)

March 31,
2026
December 31,
2025ASSETS


Current assets:


Cash and cash equivalents$          6,804
$            7,575Short-term investments—
994Accounts receivable, net163
201Inventory1,048
994Prepaid expenses and other current assets338
297Total current assets8,353
10,061Right to use asset, operating lease2,295
2,336Property and equipment, net379
410Other noncurrent assets36
36Total assets$        11,063
$          12,843



LIABILITIES AND STOCKHOLDERS' EQUITY


Current liabilities:


Accounts payable$             115
$               183Accrued expenses593
383Current portion of operating lease liability142
139Current portion of notes payable63
61Deferred revenue25
32Total current liabilities938
798Operating lease liability, less current portion2,296
2,332Notes payable, less current portion128
145Total liabilities3,362
3,275Stockholders' equity:


Common stock5
5Additional paid-in capital152,239
152,043Accumulated deficit(144,543)
(142,480)Total stockholders' equity7,701
9,568Total liabilities and stockholders' equity$        11,063
$          12,843 SENESTECH, INC.STATEMENTS OF OPERATIONS(In thousands, except share and per share data)(Unaudited)

Three Months Ended
March 31,
2026
2025Revenues, net$          493
$          485Cost of sales155
172Gross profit338
313Operating expenses:


Research and development422
418Selling, general and administrative2,035
1,558Total operating expenses2,457
1,976Loss from operations(2,119)
(1,663)Interest income (expense), net56
(2)Net loss$      (2,063)
$      (1,665)Weighted average shares outstanding — basic and diluted5,263,717
1,299,971Loss per share — basic and diluted$        (0.39)
$        (1.28) SENESTECH, INC.Itemized Reconciliation Between Net Loss and Adjusted EBITDA (non-GAAP)(In thousands)(Unaudited)

Three Months Ended
March 31,
2026
2025Net loss (as reported, GAAP)$      (2,063)
$      (1,665)Non-GAAP adjustments:


Severance costs230
27One-time legal costs213
45Interest income, net(56)
2Stock-based compensation expense23
91Depreciation expense31
39Non-cash operating lease expense8
—Total non-GAAP adjustments449
204Adjusted EBITDA loss (non-GAAP)$      (1,614)
$      (1,461) SenesTech Inc.Reconciliation of Net Loss and Adjusted Net Loss (non-GAAP)(In thousands)(Unaudited)

Three Months Ended
March 31,
Percent
Change
2026
2025
Net loss (as reported, GAAP)$        (2,063)
$        (1,665)
24 %Non-GAAP adjustments:




Severance costs230
27

One-time legal costs213
45

Adjusted net loss (non-GAAP)$        (1,620)
$        (1,593)
2 %  View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-reports-record-direct-to-consumer-and-subscription-growth-following-strategic-e-commerce-transition-302769942.htmlSOURCE SenesTech, Inc. Original: SenesTech Reports Record Direct-to-Consumer and Subscription Growth Following Strategic E-Commerce Transition

SenesTech to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026May 7, 2026 4:30 PM
PR Newswire (US) Financial results to be released after market close;
Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, May 7, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products, will report financial results for its first quarter 2026, ended March 31, 2026, after the market close on Tuesday, May 12, 2026. The Company has scheduled a conference call that same day, Tuesday, May 12, 2026, at 5:00 pm ET, to review the results. First Quarter 2026 Conference Call DetailsDate and Time: Tuesday, March 12, 2026, at 5:00 p.m. Eastern timeLive Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://app.webinar.net/m976bqQblKE or http://senestech.investorroom.com/.Replay: A webcast replay will be available in the Investor Relations section of the Company's website at http://senestech.investorroom.com/ for at least 90 days.About SenesTech
SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The Company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are humane, effective and sustainable.For more information, visit https://senestech.com. Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby.  Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases.  You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements.  Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations;  and regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.  All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date.  Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. CONTACT: Investor: Robert Blum, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.comCompany: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143 View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-to-report-first-quarter-2026-financial-results-on-tuesday-may-12-2026-302766056.htmlSOURCE SenesTech, Inc. Original: SenesTech to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-CommerceMarch 12, 2026 4:05 PM
PR Newswire (US)

SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025.







2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate revenue would have increased by approximately 30%. As the transition becomes fully integrated, direct Amazon management is expected to meaningfully enhance both revenue and operating margins in the future.Gross profit margin was 62.5% in 2025, compared to 54.1% in 2024, driven by the higher margin profile of the Evolve product line and manufacturing improvements.Net loss for 2025 was $6.4 million compared to $6.2 million in 2024. 2025 included $631,000 in one-time legal expenses and $135,000 in non-cash operating lease expense. Excluding these items, Adjusted Net Loss would have been $5.6 million.Adjusted EBITDA loss improved to $5.3 million in 2025, compared to $5.8 million in 2024, reflecting continued revenue growth and improved gross margins partially offset by higher operating investments.The balance sheet was strengthened by capital raises completed in 2025, resulting in cash and short-term investments of $8.6 million at the end of 2025. The Company believes this capital will be sufficient to provide operating runway through approximately the second quarter of 2027.Operational and Strategic HighlightsE-commerce Growth: E-commerce revenue increased 88% year-over-year from 2024 to 2025, driven by strong growth on Amazon and the Company's direct-to-consumer website, notwithstanding the loss of an estimated $200,000 in 2025 revenue as a result of the Company's transition to directly managing Amazon sales. If the Company had recognized an additional $200,000 in E-Commerce revenue for this transition, E-Commerce revenue growth would have been 130%.Amazon Direct Management: SenesTech has begun directly managing Amazon sales of Evolve Rat and Evolve Mouse, transitioning from third-party management to strengthen product presentation and customer communications, leverage performance data to optimize marketing, and retain a greater portion of e-commerce economics. While the transition created an approximately $200,000 fourth quarter revenue impact, management expects direct control to drive higher revenue and stronger margins once fully integrated.Field Validation: Multi-month Evolve deployments in two urban study areas delivered measurable reductions in rodent activity within five months, including a 79% decline in rat activity at one site and more than a 50% decline at a second site.International Expansion: Evolve secured regulatory approval in New Zealand (with the initial stocking order shipped to exclusive partner Evicom) and expanded international footprint in Belize by adding the Belize Raptor Center as an official distributor.CEO Transition: SenesTech's Board has initiated a formal search for a new CEO following Joel Fruendt's retirement, and appointed Dr. Jamie Bechtel to the newly created role of Interim Executive Chair to support leadership continuity and strategic execution during the transition period.Commentary"2025 marked meaningful progress, with continued field validation, revenue growth, improved margins, and a stronger balance sheet," said Joel Fruendt, President and CEO of SenesTech. "We believe field validation of efficacy becomes a powerful catalyst for expanded acceptance in the market, as reflected in the strong growth of our e-commerce channel, which is now more than 50% of our annual revenue. We are leaning further into the direct-to-consumer and e-commerce opportunities, strengthening our control of the customer experience, improving performance management, and enhancing our ability to capture more value as adoption expands.""With a CEO transition plan underway, the Board remains focused on continuity, alignment, and disciplined execution as we support management in scaling the business," said Dr. Jamie Bechtel, Interim Executive Chair of SenesTech. "With a growing body of validation and a sharpened go-to-market approach, we are focused on executing with discipline, expanding adoption, and building long-term stockholder value."Use of Non-GAAP Financial MeasureAdjusted EBITDA and Adjusted Net Loss are non-GAAP measures. However, these measures are not intended to be a substitute for those financial measures reported in accordance with GAAP. These have been included because management believes that, when considered together with the GAAP figures, they provide meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. We use these non-GAAP financial measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. These adjustments may be calculated by us differently than other companies that disclose measures with the same or similar term. See our attached financials for a reconciliation of the non-GAAP measures to the nearest GAAP measure.Conference Call DetailsDate and Time: Thursday, March 12, 2026, at 5:00 pm ETLive Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available in the Investor Relations section of the Company's website at https://app.webinar.net/g3BpDpdDZ14 or https://senestech.investorroom.com/. Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://senestech.investorroom.com/ for 90 days.About SenesTechSenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.For more information visit https://senestech.com/. Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, statements regarding the effectiveness and benefits of our products; the potential of direct management of Amazon sales of Evolve products to meaningfully enhance both revenue and operating margins; the Company's expected operating runway; the potential of field validation of efficacy to expand acceptance in the market; the Company's plans to lean further into direct-to-consumer and e-commerce opportunities and potential benefits thereof; CEO transition matters; and the impact of Adjusted EBITDA and Adjusted Net Loss metrics.Forward-looking statements may describe future expectations, plans, results, or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; regulatory approval and regulation of our products; challenges transitioning to direct management of Amazon sales of Evolve products or the results of such direct management not being as expected; having to use cash at times and in ways other than as planned; and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACT:  Investor Relations: Robert Blum, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.comCompany: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143SENESTECH, INC.
BALANCE SHEETS
(In thousands, except share and per share data)
(Unaudited)

As of December 31,
2025
2024ASSETS


Current assets:


Cash and cash equivalents$         7,575
$         1,307Short-term investments994
—Accounts receivable, net201
335Inventory994
794Prepaid expenses and other current assets297
377Total current assets10,061
2,813Right to use assets, operating leases2,336
—Property and equipment, net410
407Other noncurrent assets36
58Total assets$       12,843
$         3,278



LIABILITIES AND STOCKHOLDERS' EQUITY


Current liabilities:


Accounts payable$           183
$           215Accrued expenses383
278Current portion of operating lease liability139
—Current portion of notes payable61
56Deferred revenue32
12Total current liabilities798
561Operating lease liability, less current portion2,332
-Notes payable, less current portion145
206Total liabilities3,275
767Stockholders' equity:


Common stock5
1Additional paid-in capital152,043
138,607Accumulated deficit(142,480)
(136,097)Total stockholders' equity9,568
2,511Total liabilities and stockholders' equity$       12,843
$         3,278 SENESTECH, INC.
STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
(Unaudited)

Three Months Ended
December 31,
Years Ended
December 31,
2025
2024
2025
2024Revenues, net$           421
$           501
$         2,221
$         1,857Cost of sales188
196
833
853Gross profit233
305
1,388
1,004Operating expenses:






Research and development453
424
1,698
1,712Selling, general and administrative1,661
1,138
6,195
5,541Total operating expenses2,114
1,562
7,893
7,253Loss from operations(1,881)
(1,257)
(6,505)
(6,249)Other income (expense):






Interest income82
8
144
56Interest expense(5)
(7)
(22)
(22)Miscellaneous income—
1
—
31Other income, net77
2
122
65Net loss$        (1,804)
$        (1,255)
$        (6,383)
$        (6,184)Weighted average shares outstanding — basic and diluted5,223,015
1,029,592
3,275,983
697,974Loss per share — basic and diluted$         (0.35)
$         (1.22)
$         (1.95)
$         (8.86) SenesTech Inc.
Itemized Reconciliation Between Net Loss and Adjusted EBITDA (non-GAAP)
(In thousands)
(Unaudited)

Three Months Ended
December 31,
Years Ended
December 31,
2025
2024
2025
2024Net loss (as reported, GAAP)$        (1,804)
$        (1,255)
$        (6,383)
$        (6,184)Non-GAAP adjustments:






Interest income, net(77)
(1)
(122)
(34)Stock-based compensation expense36
80
264
326Depreciation expense32
41
135
156Non-cash operating lease expense (benefit)48
(5)
135
(8)One-time legal costs275
—
631
—Severance costs-
-
27
13Gain on sale of assets-
-
—
(28)Total non-GAAP adjustments314
115
1,070
425Adjusted EBITDA loss (non-GAAP)$        (1,490)
$        (1,140)
$        (5,313)
$        (5,759) SenesTech Inc.
Reconciliation of Net Loss and Adjusted Net Loss (non-GAAP)
(In thousands)
(Unaudited)

Years Ended
December 31,
Percent Change
2025
2024
Net loss (as reported, GAAP)$        (6,383)
$        (6,184)
3 %Non-GAAP adjustments:




One-time legal costs631
—

Non-cash operating lease expense (benefit)135
(8)

Adjusted net loss (non-GAAP)$        (5,617)
$        (6,192)
(9) %   



View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-2025-financial-results-driven-by-strong-growth-in-e-commerce-302712612.htmlSOURCE SenesTech, Inc.

Original: SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026March 9, 2026 4:15 PM
PR Newswire (US)

Financial results to be released after market close; 
Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results.







Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDate and Time: Thursday, March 12, 2026, at 5:00 p.m. Eastern timeLive Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://app.webinar.net/g3BpDpdDZ14 or http://senestech.investorroom.com/. Replay: A webcast replay will be available in the Investor Relations section of the Company's website at http://senestech.investorroom.com/ for at least 90 days.About SenesTech
SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.For more information, visit https://senestech.com. Safe Harbor Statement 
This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby.  Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases.  You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements.  Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; our ability to regain and maintain compliance with Nasdaq's continued listing requirements; and regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.  All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date.  Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.CONTACT: Investor: Robert Blum, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.comCompany: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143



View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-on-thursday-march-12-2026-302707177.htmlSOURCE SenesTech, Inc.

Original: SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

SenesTech Announces CEO Transition PlanJanuary 28, 2026 4:05 PM
PR Newswire (US)

Board To Initiate Search For New Leadership As Current CEO Plans RetirementDr. Jamie Bechtel Named Interim Executive Chair To Further Support TransitionPHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.







Mr. Fruendt joined SenesTech in 2022 and has overseen the Company's development and launch of its revolutionary new product, Evolve®, across multiple retail and professional channels.In addition, to further support this transition, the Board has appointed Dr. Jamie Bechtel, current Chair of the Board, to the newly created role of Interim Executive Chair. In this role, Dr. Bechtel will partner with management to support strategic alignment, execution discipline, and clear communication between the Board and the leadership team. This position is intended to reinforce management accountability and ensure continuity – without assuming day-to-day operational responsibilities."Joel has played a pivotal role in positioning SenesTech for future growth, particularly through the successful launch of Evolve®, and a renewed focus on operational execution," said Dr. Jamie Bechtel, Chair of the Board. "We are grateful for his leadership and his dedication to the Company's mission.""It has been a privilege to lead the SenesTech team through this important chapter in the Company's growth," said Fruendt. "We've made strong progress expanding access to our effective and sustainable fertility control solutions, and I'm proud of what we've accomplished together. As I plan for my retirement, I remain committed to supporting a smooth and thoughtful transition.""The Board has full confidence in a smooth and orderly transition, supported by our strong management team. Interim COO Michael Edell and CFO Tom Chesterman will continue leading the day-to-day execution of our plans," added Dr. Bechtel. "As Interim Executive Chair, I will be supporting the management team during this transitional period by helping ensure strategic alignment, execution discipline, and clear communication between the Board and the organization."The Board will engage an executive search firm to assist in identifying a qualified successor to lead SenesTech in its next chapter.About SenesTech, Inc.
SenesTech is committed to creating healthier environments by humanely managing animal pest populations through fertility control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are humane, effective, and sustainable.For more information, visit https://senestech.com. Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. These include, but are not limited to, the successful commercialization of our products, regulatory approvals, and market acceptance. SenesTech does not undertake any obligation to update forward-looking statements except as required by law.Company Contact:
Tom Chesterman, CFO
(928) 233-7533



View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-ceo-transition-plan-302673042.htmlSOURCE SenesTech, Inc.

Original: SenesTech Announces CEO Transition Plan

I'm in. Hello?

SNES...........................................https://stockcharts.com/h-sc/ui?s=SNES
&p=W&b=5&g=0&id=p86431144783

SNES.........................................................p/m

$2.61 +'13%!Low float rat power .. https://www.sec.gov/Archives/edgar/data/1680378/000162828025012340/snes-20250312xexx991.htm

SNES SenesTech Summary
Second Mouse (Google Doc)

SNES SECOND ROUND POP

SNES MONSTER

just WoW...!

1-Mil. float - just INSANE...!

"As we finish 2024, we have a number of initiatives set to be significant contributors to top line growth, including the recent approval to sell Evolve on third party e-commerce platforms; multiple large international orders set to ship before the end of the year; adoption by key brick-and-mortar retailers; potential deployment in New York City and other key municipalities; and broader adoption of our new Evolve Rat and Mouse solutions through existing channels."

"As the only manufacturer of products registered or designated by the U.S. EPA for the restriction of rodent reproduction, we have a tremendous opportunity ahead of us to 'Change the Game' of how the rodent control industry addresses rodent infestations. With Evolve, and its improved form factor, economical price point, proven efficacy, and lengthy shelf life, we have addressed all the key product attribute requirements communicated to us by the industry. We look forward to continued rapid adoption of our innovative solutions." Fruendt concluded.

nice revenues, nice Big Box expansiuon of product, nice revenues incoming, proprietray products expanding across all borders - nice...

EOM

SNES ROCK STAR OF THE DAY

SenesTech - >>> New York City Council passes bill to use birth control on rats


WPIX New York

by Matthew Euzarraga

September 26, 2024


https://www.yahoo.com/news/york-city-council-passes-bill-221403507.html


NEW YORK (PIX11) — The New York City Council voted Thursday to use birth control on rats.

According to the bill, a local rat contraceptive pilot program will begin in a small section of the city 180 days after the bill is passed.

“For no less than 12 months immediately after the deployment of the rat contraceptive, the department shall perform monthly inspections of each pilot program area and each pilot program comparison area,” read the newly passed bill. “During such monthly inspections of the pilot program areas, the department shall track the amount of rat contraceptive in each rat contraceptive dispenser.”

The pilot program is inspired by New York City’s beloved Flaco the owl, who died earlier this year with rat poison in his system.

New York City Council member Shaun Abreu, the bill’s sponsor, said he has worked with ContraPest, a type of birth control, to find a less harmful way to reduce the New York City rat population. Abreu also noted that other steps, such as having New Yorkers put trash in containers, will make the contraceptive more effective.

ContraPest has been utilized by the city in the past, but it was not practical, according to a veterinarian with over 12 years of experience who spoke to PIX11 News.

To have dry powder in this company!

Waiting For Happy Hour!

This could explode and running like a white horse!

It would be nice to get more buying volume.....the news was probably expected.....Still,Green on a red day is welcomed

https://finance.yahoo.com/news/senestech-signs-expanded-distribution-agreement-140000018.html

SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations, today announces the expansion ...

earnings per share estimates for shares of SenesTech in a research report issued on Thursday, December 28th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings of ($30.28) per share for the year, up from their prior estimate of ($45.74). HC Wainwright has a “Buy” rating and a $3.50 price target on the stock. The consensus estimate for SenesTech’s current full-year earnings is ($30.28) per share

Definitely seems like it could be.... wouldn't expect much for Tues/Wed.... hopefully it stabilizes and works it's way to the 1.40s.....Gotta think,with some good news....It could run...

I think it is runner as well as the orders make this more desirable. They have a good product that is raising interest. I'm thinking MMs lowered this Friday to have shares to sell next Tuesday. 3 day weekends are rare, so big group of buyers on Tuesday ? That's my take on it .

Well...I guess there it is a 1 day.......yikes...if it could just go back to the 1.40s LOL

Hate to say it....But it seems like a lot of shares have traded to get a %116 rise...Idk

It's got a tiny float so it could go sky-high. Very erratic trading

Got in way late at 1.48....probably regret it lol

Excellent call brother. :)

Winner winner$$$

I don’t think it matters right now. This is a runner. Expecting 2+ today IMO

Figure this out = The number of shares of common stock outstanding as of November 8, 2023: 3,631,060

China

Whats the good word?

Easy $

SNES new 52 week low

Dilution approved.

R/S approved.

Hard not to laugh at that AH

SenesTech Launches EVOLVE Soft Bait Fertility Solution in California-based Ace Hardware Franchise Locations
PHOENIX, Nov. 27, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the leader in fertility control to manage animal pest populations, today announced the launch of Evolve™ Soft Bait ("Evolve") at Ace Hardware franchise locations in California. Evolve is the first and only soft bait product featuring breakthrough, next generation technology that targets rodent populations by using nonlethal methods to restrict fertility. The franchise has also recently began selling SenesTech's expanded line of fertility control products, including the Isolate™ and Elevate™ bait systems for ContraPest®. This marks the first time a traditional retail store has offered SenesTech's rodent fertility control solutions.


"California-based Scarborough Ace Hardware, as well as Scarborough Home and Garden, are the first retail outlets to commit to SenesTech's line. They will also be among the first in the U.S. to receive shipments of Evolve based on their recent preorder," commented Joel Fruendt, SenesTech's President and Chief Executive Officer. "We expect the penetration of retail and big box to rapidly accelerate, especially with the launch of Evolve and its retail friendly soft bait profile and packaging."

Evolve addresses the fundamental issue of rodent overpopulation by focusing on the rapid reproduction of rats. Evolve controls the population by reducing or eliminating the fertility of rats, rather than trying to keep up with the growing numbers of an infestation with poisons alone. The active ingredient in Evolve effectively reduces fertility in rodents in numerous independent studies. Evolve is highly palatable to rats, easy to deploy, offers diverse placement in many different environments and is priced competitively to rodenticide alternatives.

"Evolve was developed to offer customers a soft bait product that has similar efficacy to ContraPest, but in a format that is easier to deploy, and is ideally suited for use by do it yourself consumers. We are pleased to be partnering with the team at Scarborough Ace Hardware to provide their customers with an innovative solution to address their rodent issues," Fruendt expanded.

Crystal Maro from Scarborough Ace Hardware commented, "We put the ContraPest product line on the shelves recently and are already re-ordering due to high sales levels. The product is definitely starting to pick up, and with the Evolve soft bait now available, we expect interest and sales to accelerate. This area was overrun with rats after the CZU fire. Traps and poison can only get you so far, and both can cause harm to local wildlife and pets. People are very excited that there is an alternative."

SNES: And right now, a new Post-Mkt. HIGH!!

SNES new 52 week low

SNES: Some suckers-bait routines in the Pre-M here, but their PRODUCT has INSANE potential!!! (Good-bye 'Mouse Traps', inter alia???? What their stuff does to RODENTS, I wish it could do to REPUBLICANS as well!!)

SenesTech Announces Third Quarter 2023 Financial Results
Revenue Growth Up 44%; Net Loss Improved by Almost $700,000

Company to Begin Shipments of Evolve Soft Bait Next Week

Expected to Be a Key Driver of Revenue Growth

PHOENIX, Nov. 9, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the leader in fertility control to manage animal pest populations, today announced financial results for the third quarter of 2023.


"We accelerated our growth trajectory during the third quarter with strong 44% year-over-year growth in revenues driven by the initiatives we have undertaken to drive sales, improve our product quality, and expand our product options," commented Joel Fruendt, SenesTech's President and Chief Executive Officer. "We expect this growth to further accelerate as we launch our Evolve Soft Bait, the first and only soft bait developed to control pest populations using a breakthrough technology that targets the rat population where it starts, by restricting fertility through nonlethal methods. We have received pre-orders and expect to start shipping product next week."

Sales growth during the third quarter was led by increases in nearly every key market segment, including agribusiness, zoos and sanctuaries, and commercial. The Company also continued to experience sequential revenue growth and an improvement of its return on marketing investment within its e-commerce platform following the successful reconfiguration of those operations earlier this year. Overall, the various initiatives led to an improvement of nearly $700,000 in its net loss and Adjusted EBITDA loss compared to the year-ago period.

Fruendt continued, "We have made several operational improvements to drive revenue growth more efficiently, with an objective of reaching profitability in the near future."

The launch of the Evolve Soft Bait is expected to be a significant step in expanding SenesTech's reach within key market verticals, including 'big box' retailers, key e-commerce channels, and pest management professionals. Evolve is highly palatable to rats, easy to deploy, and offers diverse placement in many different and complex environments, including municipalities, parks, recreation facilities, sports venues, food processing facilities, correctional facilities, subways, medical facilities, agribusiness, zoos, and residential locations. Importantly, Evolve is priced competitively to currently available rodenticide alternatives.

"Our initial focus will be on the commercial market and key industry distributors. In addition, we have established our vendor account with Amazon and are pursuing the process of selling through their portal, as well as other e-commerce providers. Finally, we are initiating discussions with key big box retailers to offer Evolve on their shelves," added Fruendt.

The introduction of Evolve continues SenesTech's recent string of innovative product offerings designed to provide customers with the effectiveness of fertility control in the format that fits their needs. In July 2023, the Isolate Bait System was launched as a more efficient and easier-to-use liquid bait system, which integrates both the tank and tray as a single unit. In October, Isolate represented over a third of all unit sales. Last year, the Company introduced Elevate, an easily deployed system for mounting in the rafters of barns, granaries, attics, lofts, and storage and manufacturing facilities. Year-to-date, nearly 5,500 Elevate systems have been deployed in various agricultural settings.

"Product innovation is key to our future success. Building upon the recent introductions of the Isolate and Elevate bait systems for ContraPest, Evolve was developed to offer customers a soft bait product that has similar efficacy to ContraPest, but in a format that is easier to deploy and in a format they can use daily in their integrated pest management programs," Fruendt continued. "A key differentiating feature for Evolve is the opportunity to distribute through key big box retailers and e-commerce providers. We are in active negotiations, with a goal to develop partnerships that will dramatically increase the adoption of the Evolve solution and to set SenesTech up for tremendous success in the future."

Q3 2023 Highlights

Revenue during Q3 2023 was $360,000 compared to $250,000 in Q3 2022, an increase of 44%.
Gross profit during Q3 2023 was $176,000, for a gross profit margin of 49%, compared to $122,000, or a gross profit margin of 49%, in Q3 2022.
Net loss during Q3 2023 was $1.9 million, compared with a net loss of $2.6 million for Q3 2022.
Adjusted EBITDA loss, which is a non-GAAP measure of operating performance, for Q3 2023 was $1.7 million compared to $2.4 million in Q3 2022.
Cash at the end of September 2023 was $2.1 million.
Use of Non-GAAP Measure

Adjusted EBITDA is a non-GAAP measure. However, this measure is not intended to substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar term. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.

Conference Call Details

Date and Time: Thursday, November 9, 2023, at 5:00 pm ET

Call-in Information: Interested parties can access the conference call by dialing (844) 308-3351 or (412) 317-5407.

Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available in the Investor Relations section of the Company's website at http://senestech.investorroom.com/ or https://app.webinar.net/J3D79bAZjVx.

Replay: A teleconference replay of the call will be available for seven days at (877) 344-7529 or (412) 317-0088, replay access code 6400460. A webcast replay will be available in the Investor Relations section of the Company's website at http://senestech.investorroom.com for 90 days or https://app.webinar.net/J3D79bAZjVx.

About SenesTech

We are committed to improving the health of the world by humanely managing animal pest populations through fertility control. We are experts in fertility control to manage animal pest populations. We invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve, an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. We strive for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable.

For more information visit https://senestech.com/ and https://contrapeststore.com.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, our expectation that the Evolve Soft Bait solution will be a key driver to revenue growth; our expectation that our growth will further accelerate into the future as we launch our Evolve Soft Bait solution; our expectation that we will start shipping Evolve Soft Bait product next week; our objective to drive the business towards profitability; our expectation that the launch of the Evolve Soft Bait solution will be a significant step in expanding our reach within key market verticals, including 'big box' retailers, key e-commerce channels, and leading industry pest management professionals; our belief that product innovation is key to our future success; and our goal to develop partnerships that will dramatically increase the adoption of the Evolve solution and set us up for tremendous success in the future. Forward-looking statements may describe future expectations, plans, results, or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; our ability to maintain compliance with Nasdaq's continued listing requirements; and regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

SNES new 52 week low

SNES new 52 week low

SNES new 52 week low